Search Results - "Cabal, Julie"

Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study by Frenel, Jean-Sebastien, Zeghondy, Jean, Guerin, Catherine, Mailliez, Audrey, Volant, Elsa, Poumeaud, Francois, Patsouris, Anne, Arnedos, Monica, Bailleux, Caroline, Cabal, Julie, Galland, Loick, De nonneville, Alexandre, Guiu Lahaye, Severine, Dalenc, Florence, Pistilli, Barbara, Bachelot, Thomas, Martin, Pierre, Bocquet, Francois, Larrouquere, Louis, Loirat, Delphine

“…1014 Background: Recent guidelines have positioned T-DXd as a preferred treatment in the second line setting for HER2+ metastatic breast cancer (MBC). TTC is…”
Get full text

Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer by Frenel, Jean-Sebastien, Zeghondy, Jean, Guérin-Charbonnel, Catherine, Mailliez, Audrey, Volant, Elsa, Poumeaud, François, Patsouris, Anne, Arnedos, Monica, Bailleux, Caroline, Cabal, Julie, Galland, Loick, de Nonneville, Alexandre, Guiu, Séverine, Dalenc, Florence, Pistilli, Barbara, Bachelot, Thomas, Pierga, Jean-Yves, Le Du, Fanny, Bocquet, François, Larrouquere, Louis, Loirat, Delphine

“…Little is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzumab-deruxtecan exposure among…”
Get full text